Pacific Biosciences Of California (PACB) Short term Debt (2021 - 2023)
Pacific Biosciences Of California has reported Short term Debt over the past 6 years, most recently at $96.2 million for Q3 2023.
- Quarterly results put Short term Debt at $96.2 million for Q3 2023, changed N/A from a year ago — trailing twelve months through Sep 2023 was $96.2 million (changed N/A YoY), and the annual figure for FY2022 was $172.1 million, up 10602.36%.
- Short term Debt for Q3 2023 was $96.2 million at Pacific Biosciences Of California, down from $186.3 million in the prior quarter.
- Over the last five years, Short term Debt for PACB hit a ceiling of $186.3 million in Q2 2023 and a floor of $1.6 million in Q4 2021.
- Median Short term Debt over the past 3 years was $172.1 million (2022), compared with a mean of $128.1 million.
- Peak annual rise in Short term Debt hit 10602.36% in 2022, while the deepest fall reached 10602.36% in 2022.
- Pacific Biosciences Of California's Short term Debt stood at $1.6 million in 2021, then surged by 10602.36% to $172.1 million in 2022, then plummeted by 44.1% to $96.2 million in 2023.
- The last three reported values for Short term Debt were $96.2 million (Q3 2023), $186.3 million (Q2 2023), and $184.4 million (Q1 2023) per Business Quant data.